Refametinib
Refametinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 6 | 1 | — | — | — | 6 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 3 | — | — | — | 3 |
| Biliary tract neoplasms | D001661 | C24.9 | — | 1 | — | — | — | 1 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | REFAMETINIB |
| INN | refametinib |
| Description | Refametinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 923032-36-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1236682 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | JPX07AFM0N (ChemIDplus, GSRS) |
Target
Agency Approved
MAP2K1
MAP2K1
MAP2K2
MAP2K2
Organism
Homo sapiens
Gene name
MAP2K1
Gene synonyms
MEK1, PRKMK1
NCBI Gene ID
Protein name
dual specificity mitogen-activated protein kinase kinase 1
Protein synonyms
ERK activator kinase 1, MAPK/ERK kinase 1, MAPKK 1, MEK 1, protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1)
Uniprot ID
Mouse ortholog
Map2k1 (26395)
dual specificity mitogen-activated protein kinase kinase 1 (P31938)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 348 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more